Celldex Therapeutics Files 8-K
Ticker: CLDX · Form: 8-K · Filed: Aug 19, 2025 · CIK: 744218
| Field | Detail |
|---|---|
| Company | Celldex Therapeutics, Inc. (CLDX) |
| Form Type | 8-K |
| Filed Date | Aug 19, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financial-statements
TL;DR
Celldex filed an 8-K on 8/19/25. Standard reporting.
AI Summary
Celldex Therapeutics, Inc. filed an 8-K on August 19, 2025, reporting other events and financial statements. The company, formerly known as AVANT IMMUNOTHERAPEUTICS INC and T CELL SCIENCES INC, is incorporated in Delaware and headquartered in Hampton, New Jersey.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and other events, which is important for investors to stay updated on the company's status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and financial statements, not indicating any immediate or significant new risks.
Key Players & Entities
- Celldex Therapeutics, Inc. (company) — Registrant
- AVANT IMMUNOTHERAPEUTICS INC (company) — Former Company Name
- T CELL SCIENCES INC (company) — Former Company Name
- August 19, 2025 (date) — Date of Report
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is August 19, 2025.
What is the principal business address of Celldex Therapeutics, Inc.?
The principal business address is Perryville III Building, 53 Frontage Road, Suite 220, Hampton, New Jersey 08827.
In which state is Celldex Therapeutics, Inc. incorporated?
Celldex Therapeutics, Inc. is incorporated in Delaware.
What were the previous names of Celldex Therapeutics, Inc.?
Celldex Therapeutics, Inc. was formerly known as AVANT IMMUNOTHERAPEUTICS INC and T CELL SCIENCES INC.
What is the SIC code for Celldex Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Celldex Therapeutics, Inc. is 2835, which corresponds to IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
Filing Stats: 428 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2025-08-19 16:04:53
Filing Documents
- tm2523903d1_8k.htm (8-K) — 25KB
- tm2523903d1_ex99-1.htm (EX-99.1) — 20KB
- tm2523903d1_ex99-1img001.jpg (GRAPHIC) — 9KB
- 0001104659-25-080248.txt ( ) — 225KB
- cldx-20250819.xsd (EX-101.SCH) — 3KB
- cldx-20250819_lab.xml (EX-101.LAB) — 33KB
- cldx-20250819_pre.xml (EX-101.PRE) — 22KB
- tm2523903d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On August 19, 2025, Celldex Therapeutics, Inc. issued a press release announcing results from its Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE). A copy of this press release is attached hereto as Exhibit 99.1 hereto and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release of Celldex Therapeutics, Inc., dated August 19, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Celldex Therapeutics, Inc. Date: August 19, 2025 By: /s/ Sam Martin Sam Martin Senior Vice President and Chief Financial Officer